The Research Program aims at: 1) Detailed characterization of immune signaling capacity of SMZL B cells, in order to obtain deeper insight into the precise role of signaling inhibitors in SMZL management, 2) screening and functional characterization of EZH2, a marker of clinical aggressiveness and druggable target in lymphoma (Wagener, Macher-Goeppinger et al. 2010, Beguelin, Popovic et al. 2013, Behrens, Solis et al. 2013), in well a characterized cohort of SMZL case, and 3) investigation of the effects and potential synergism of combined EZH2 and signaling inhibition in SMZL cells ex vivo.
